文献速递脊柱关节炎

全身磁共振成像缓解标准揭示戈利木单抗治疗中轴型脊柱关节炎炎症减轻

Novel whole-body magnetic resonance imaging response and remission criteria document diminished inflammation during golimumab treatment in axial spondyloarthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究纳入53例中轴型脊柱关节炎患者,在戈利木单抗治疗第0、4、16、52周行全身磁共振成像(WB-MRI),评估中轴及外周关节和附着点炎症。结果显示WB-MRI可见骶髂关节、脊柱及外周关节附着点炎症显著减轻,但达到全身WB-MRI缓解者极少;将脊柱与骶髂关节炎症合并为MRI中轴炎症指数可提高捕捉治疗反应的能力。

要点

  • 戈利木单抗治疗第52周,WB-MRI显示骶髂关节和脊柱炎症至少50%改善者分别占60%和58%。
  • 全身WB-MRI完全缓解率低,第4、16、52周分别为4%、11%和6%。
  • 第16周MRI中轴炎症指数至少50%改善者中83%达BASDAI50、100%达ASDAS-CII。

核心结论

  • 戈利木单抗治疗中轴型脊柱关节炎可显著减轻脊柱、骶髂关节及外周关节和附着点的WB-MRI炎症。
  • 达到全身WB-MRI缓解的患者比例很低。
  • 将脊柱与骶髂关节炎症合并为MRI中轴炎症指数可提高捕捉治疗反应的能力。

研究设计与样本

  • 研究者发起的队列研究,纳入53例开始戈利木单抗治疗的中轴型脊柱关节炎患者。
  • 在第0、4、16、52周行WB-MRI,采用加拿大脊柱关节炎研究联盟MRI骶髂关节炎症指数、加拿大-丹麦MRI脊柱炎症评分及MRI外周关节和附着点炎症指数评估。

主要发现

  • 第4、16、52周骶髂关节MRI炎症至少50%改善者分别为16、29、32例(30%、55%、60%)。
  • 第4、16、52周脊柱MRI炎症至少50%改善者分别为20、30、31例(38%、57%、58%)。
  • 第4、16、52周外周关节和附着点MRI炎症至少50%改善者分别为8、17、15例(15%、32%、28%)。
  • 第4、16、52周BASDAI50应答者分别为29、31、31例(55%、58%、58%),ASDAS临床重要改善(ASDAS-CII)者分别为37、40、34例(70%、75%、64%)。
  • 第4、16、52周达到全身WB-MRI缓解者分别为2、6、3例(4%、11%、6%)。

关键数值与推荐

  • WB-MRI炎症改善定义为骶髂关节、脊柱或外周关节和附着点MRI炎症较基线至少减少50%。
  • BASDAI50应答定义为BASDAI改善至少50%。
  • ASDAS-CII定义为ASDAS临床重要改善。
  • 全身WB-MRI缓解标准为脊柱、骶髂关节及外周关节和附着点均达到WB-MRI缓解。

临床怎么用

  • WB-MRI可用于评估中轴型脊柱关节炎患者戈利木单抗治疗后的炎症变化。
  • 临床可关注MRI中轴炎症指数(合并脊柱与骶髂关节炎症)以更好捕捉治疗反应。
  • 全身WB-MRI缓解率低,临床不应以全身WB-MRI缓解作为多数患者的治疗目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate criteria for treatment response and remission in patients with axial SpA as assessed by whole-body magnetic resonance imaging (WB-MRI) of axial and peripheral joints and entheses during treatment with golimumab. METHODS: We performed an investigator-initiated cohort study of 53 patients who underwent WB-MRI at weeks 0, 4, 16 and 52 after initiation of golimumab. Images were assessed according to the Spondyloarthritis Research Consortium of Canada MRI SI joint inflammation index, Canada-Denmark MRI spine inflammation score and the MRI peripheral joints and entheses inflammation index. RESULTS: At weeks 4, 16 and 52, WB-MRI demonstrated an at least 50% reduction of MRI inflammation of the sacroiliac joints in 16, 29 and 32 (30%, 55% and 60%) patients, of the spine in 20, 30 and 31 (38%, 57% and 58%) patients and of peripheral joints and entheses in 8, 17 and 15 (15%, 32% and 28%) patients, respectively. The BASDAI50 response was achieved by 29, 31 and 31 (55%, 58% and 58%) patients, while ASDAS clinically important improvement (ASDAS-CII) was achieved by 37, 40 and 34 (70%, 75% and 64%) patients. WB-MRI remission criteria for spine, sacroiliac joints and peripheral joints and entheses were explored; total WB-MRI remission was attained by 2, 6 and 3 (4%, 11% and 6%) patients. At week 16, among 35 patients with an at least 50% reduction in the MRI Axial Inflammation Index (sacroiliac joint and spine inflammation), 29 (83%) achieved BASDAI50 and 35 (100%) achieved ASDAS-CII; among 16 patients with MRI axial inflammation non-response, 14 (88%) were BASDAI50 non-responders and 11 (69%) did not achieve ASDAS-CII. CONCLUSION: WB-MRI demonstrated a significant reduction of inflammation in both the spine, sacroiliac joints and peripheral joints and entheses during golimumab treatment. Few patients achieved total WB-MRI remission. Combining spinal and sacroiliac joint inflammation in an MRI Axial Inflammation Index increased the ability to capture response. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02011386.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Krabbe S, Eshed I, Sørensen IJ, et al. Novel whole-body magnetic resonance imaging response and remission criteria document diminished inflammation during golimumab treatment in axial spondyloarthritis. Rheumatology (Oxford). 2020. PMID: 32310294. doi:10.1093/rheumatology/keaa153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。